174 related articles for article (PubMed ID: 7655127)
1. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis.
Oster G; Huse DM; Lacey MJ; Regan MM; Fuchs HJ
Ann Pharmacother; 1995 May; 29(5):459-64. PubMed ID: 7655127
[TBL] [Abstract][Full Text] [Related]
2. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
3. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
[TBL] [Abstract][Full Text] [Related]
5. Use of rhDNase therapy and costs of respiratory-related care in patients with cystic fibrosis.
Ollendorf DA; McGarry LJ; Watrous ML; Oster G
Ann Pharmacother; 2000 Mar; 34(3):304-8. PubMed ID: 10917374
[TBL] [Abstract][Full Text] [Related]
6. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
8. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
9. Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis--an overview.
Hodson ME
Respiration; 1995; 62 Suppl 1():29-32. PubMed ID: 7792438
[TBL] [Abstract][Full Text] [Related]
10. Comment: cost of rhDNase in cystic fibrosis.
Marra CA; Carleton BC; Basmadjian D; Levine M; McKerrow R
Ann Pharmacother; 1995 Oct; 29(10):1050-1. PubMed ID: 8845550
[No Abstract] [Full Text] [Related]
11. Recombinant human deoxyribonuclease for cystic fibrosis.
Jones AP; Wallis CE
Cochrane Database Syst Rev; 2003; (3):CD001127. PubMed ID: 12917899
[TBL] [Abstract][Full Text] [Related]
12. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis.
Menzin J; Oster G; Davies L; Drummond MF; Greiner W; Lucioni C; Merot JL; Rossi F; vd Schulenburg JG; SouĂȘtre E
Int J Technol Assess Health Care; 1996; 12(1):52-61. PubMed ID: 8690562
[TBL] [Abstract][Full Text] [Related]
13. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.
Wilmott RW; Amin RS; Colin AA; DeVault A; Dozor AJ; Eigen H; Johnson C; Lester LA; McCoy K; McKean LP; Moss R; Nash ML; Jue CP; Regelmann W; Stokes DC; Fuchs HJ
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1914-7. PubMed ID: 8665055
[TBL] [Abstract][Full Text] [Related]
14. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis.
Suri R; Grieve R; Normand C; Metcalfe C; Thompson S; Wallis C; Bush A
Thorax; 2002 Oct; 57(10):841-6. PubMed ID: 12324668
[TBL] [Abstract][Full Text] [Related]
15. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials of recombinant human DNase in cystic fibrosis patients.
Aitken ML
Monaldi Arch Chest Dis; 1993 Dec; 48(6):653-6. PubMed ID: 8124306
[TBL] [Abstract][Full Text] [Related]
18. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
[TBL] [Abstract][Full Text] [Related]
19. [Clinical development of rhDNase in the United States].
Eisenberg J
Arch Pediatr; 1995 Jul; 2(7):674-8. PubMed ID: 7663659
[TBL] [Abstract][Full Text] [Related]
20. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]